Literature DB >> 17419281

Clinicopathological and immunohistochemical markers after radical gastrectomy for gastric cancer.

Stojan Potrc1, Eldar Gadiijev, Tine Hajdinjak, Rajko Kavalar.   

Abstract

BACKGROUND/AIMS: The aim of the study was to verify the classic clinicopathological prognostic factors of the expected survival, to determine the frequency of immunohistochemical factors (C-erB-2, p53) and to verify these immunohistochemical factors in their function as prognostic factors in gastric cancer patients after a potentially curative gastric resection.
METHODOLOGY: In 78 gastric cancer patients after a potentially curative resection the clinicopathological factors (age, general performance of the patient, tumor diameter, TNM stage, stage according to UICC, type of operation and the extent of lymphadenectomy) and immunohistochemical factors (p53 and C-erB-2) were analyzed.
RESULTS: In univariate analysis ASA stage of general performance, size of tumor, TNM stage and stage according to UICC exert significant influence on the median survival. Median survival is higher in patients with C-erB-2 negative reaction and in those with p53 positive reaction, although not significant. In patients with tumor located in proximal two thirds, patients with negative reaction to C-erB-2 have a significantly higher median survival than patients with positive reaction to C-erB-2. The Cox regression model reveals ASA stage and UICC classification to be significant factors whereas immunohistochemical parameters C-erB-2 and p53 do not reveal any significance in the multivariate survival analysis.
CONCLUSIONS: According to the results of our study the ASA stage and UICC classification influence the expected survival of potentially radically resected gastric cancer patients significantly, while immunohistochemical parameters C-erB-2 and p53 do not.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17419281

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

1.  The prognostic significance of p53 expression in gastric cancer: a meta-analysis.

Authors:  Kongkong Wei; Lei Jiang; Yaoyao Wei; Yufeng Wang; Xuankun Qian; Qiang Dai; Quanlin Guan
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-15       Impact factor: 4.553

2.  Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.

Authors:  Ming-Ming He; Dong-Sheng Zhang; Feng Wang; Zhi-Qiang Wang; Hui-Yan Luo; Chao Ren; Ying Jin; Dong-Liang Chen; Rui-Hua Xu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

3.  Overexpression of eukaryotic elongation factor 1 alpha-2 is associated with poorer prognosis in patients with gastric cancer.

Authors:  Song Yang; Mingdian Lu; Yuanyuan Chen; Delong Meng; Ruochuan Sun; Dapeng Yun; Zhijie Zhao; Daru Lu; Yongxiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-20       Impact factor: 4.553

4.  Clinicopathological differences, risk factors and prognostic scores for western patients with intestinal and diffuse-type gastric cancer.

Authors:  Cristina Díaz Del Arco; Lourdes Estrada Muñoz; Luis Ortega Medina; Elena Molina Roldán; M Ángeles Cerón Nieto; Soledad García Gómez de Las Heras; M Jesús Fernández Aceñero
Journal:  World J Gastrointest Oncol       Date:  2022-06-15

5.  Expression of COX-2 in stomach carcinogenesis.

Authors:  Nora Manoukian Forones; Kharen Yaemi Kawamura; Helena Regina Comodo Segreto; Ricardo Artigiani Neto; Gustavo Rubino de Azevedo Focchi; Celina Tizuko Fujiyama Oshima
Journal:  J Gastrointest Cancer       Date:  2008-12-24

6.  Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.

Authors:  Guan Zhen Yu; Ying Chen; Jie Jun Wang
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-01       Impact factor: 4.553

7.  Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer.

Authors:  Xuechao Liu; Pengfei Xu; Haibo Qiu; Jianjun Liu; Shangxiang Chen; Dazhi Xu; Wei Li; Youqing Zhan; Yuanfang Li; Yingbo Chen; Zhiwei Zhou; Xiaowei Sun
Journal:  Onco Targets Ther       Date:  2016-02-26       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.